Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy

Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01884168

Enrollment

Registered

2013-06-21

Start date

2013-03-31

Completion date

2023-05-31

Last updated

2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor

Brief summary

To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor presenting malignant cavity effusion after DC-CIK immunotherapy.

Detailed description

1. The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally. 2. Malignant cavity effusion from cancer patients is obtained through puncture and is centrifugalized to get supernatant fluid and enrich cancer cells before and after the therapy. 3. The enriched cancer cells which are flash frozen, as well as the supernatant, are stored at -80°C until processing. 4. The T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion. 5. Statistical analysis is performed using unsupervised hierarchical cluster.

Interventions

BIOLOGICALDc-CIK immunotherapy

The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Histologically confirmed with malignant tumor and malignant cavity effusion. 2. An Eastern Cooperative Oncology Group（ECOG）performance status of 0-2. 3. Normal cardiac, hepatic, renal and bone marrow functions. 4. Life expectancy \>3 months. 5. Not receive other anti-tumor treatment. 6. Not receive chemotherapy in pleural and abdominal cavity.

Exclusion criteria

1. Previous history of other malignancies. 2. Serious or uncontrolled concurrent medical illness.

Design outcomes

Primary

Measure	Time frame	Description
Immunotherapy response	1 month	T-Cell Receptor and B-Cell Receptor gene expression profiling and the change of cytokines, lymphocytes subpopulation before and after DC-CIK infusion

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026